

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

**royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation							
Given Name (First Name) Connie	2. Surname (Last Name) Lee Batlevi		ne)	3. Date 24-January-2021				
4. Are you the corresponding author?	Yes No Corres			onding Author's Name				
5. Manuscript Title Novel targeted agents for Follicular lym	phoma							
6. Manuscript Identifying Number (if you kr AOL-20-45	now it)							
Section 2. The Work Under Co	onsidera	tion for P	ublication					
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)?	but not lin	nited to gran	its, data monitoring	-	•	c.) for		
Are there any relevant conflicts of interest? Yes Vo								
Costion 2								
Section 3. Relevant financial	activitie	s outside 1	the submitted	work.				
Place a check in the appropriate boxes in of compensation) with entities as described to clicking the "Add +" box. You should rej	bed in the	instruction	ns. Use one line fo	or each e	ntity; add as many lines as you need	d by		
Are there any relevant conflicts of intere		·	No					
If yes, please fill out the appropriate info	ormation b	pelow.						
						ı		
Name of Entity	Grant?	Fees?	Non-Financial Support?	Other?	Comments			
Janssen			Jupport• ✓		clinical trial support			
Novartis			<b>✓</b>		clinical trial support			
Epizyme		<b>✓</b>	<b>✓</b>		clinical trial support, consulting/ advisory board			
Bayer			<b>✓</b>		clinical trial support			
Autolus			<b>✓</b>		clinical trial support			
Roche			<b>✓</b>		clinical trial support			
BMS/Celgene/Juno		<b>V</b>			consulting/advisory board			



Name of Entity	Grant	Fees?	Support?	Other?	Comments	
(ite/Gilead		<b>✓</b>			consulting/advisory board	
Caryopharm		<b>✓</b>			consulting/advisory board	
G Therapeutics		<b>✓</b>			consulting/advisory board	
Section 4. Intellectual Propert	y Pate	ents & Cop	pyrights			
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	int to the	work? Yes No	
Section 5. Relationships not covered above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
✓ Yes, the following relationships/conditions/circumstances are present (explain below):						
No other relationships/conditions/circumstances that present a potential conflict of interest						
Stock ownership in Pfizer, BMS, Regenero	on, Viatris	s with less t	han \$10,000 USD	value.		

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.



### Section 6. Discl

#### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Lee Batlevi reports non-financial support from Janssen, non-financial support from Novartis, personal fees and non-financial support from Epizyme, non-financial support from Bayer, non-financial support from Autolus, non-financial support from Roche, personal fees from BMS/Celgene/Juno, personal fees from Kite/Gilead, personal fees from Karyopharm, personal fees from TG Therapeutics, outside the submitted work; and Stock ownership in Pfizer, BMS, Regeneron, Viatris with less than \$10,000 USD value.

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

Morschhauser

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

1

administrative support, etc.



Section 1. Identifying Inform	ation					
Given Name (First Name)  Franck	2. Surname (Last Nar Morschhauser	me)	3. Date 24-January-2021			
4. Are you the corresponding author?	✓ Yes No					
5. Manuscript Title Novel targeted agents for follicular lymp	bhoma					
6. Manuscript Identifying Number (if you kn AOL-20-45	ow it)					
Section 2. The Work Under Co	nsideration for P	ublication				
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere	but not limited to grar				tc.) for	
Section 3. Relevant financial a	activities outside	the submitted	work.			
Place a check in the appropriate boxes in of compensation) with entities as descril clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	oed in the instruction ort relationships that st?    Yes    rmation below.	ns. Use one line fo it were <b>present d</b> No	or each ent	tity; add as many lines as you nee	d by	
Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments		
Roche/genetech				advisory boards, consultancy and scinetific lectures		
Celgene/BMS				advisory boards		
Abbvie				advisory boards		
gilead				advisory boards		
epizyme				advisory boards		
genmab				advisory boards		

Morschhauser 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Morschhauser reports personal fees from Roche/genetech, personal fees from Celgene/BMS, personal fees from Abbvie, personal fees from gilead, personal fees from epizyme, personal fees from genmab, outside the submitted work; .

## **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Morschhauser 3